TrialPloS one2013

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.

Manish A Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.